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Navarro-Le´rida et al. (2015) report in this issue ofDevelopmental Cell that RAC1 nuclear accumulation causes
actin-dependent deformation of the nuclear envelope and increases nuclear plasticity. It further leads to
depletion of cytoplasmic, active RAC1 with a concomitant increase in RHOA signaling driving actomyosin-
mediated cell shape changes. These two properties combine to enhance tumor cells invasiveness.RAC1,amemberof theRHOfamilyof small
GTPases, controls a wide array of cellular
functions, including actin remodeling for
cell ruffling, adherens junction formation,
cell motility, and polarity. RAC1 has also
been implicated in cellular transformation
andcancerprogressionvia its role incell in-
vasion (Bosco et al., 2009). A key function
ofRAC1 is the control of ARP2/3-mediated
branched actin polymerization, which is
required for the formation of membrane
protrusions that drive mesenchymal mo-
tility in virtually all cells, including cancer
cells (Bisi et al., 2013). Notably, metastatic
cancer cells negotiate the diverse micro-
environmental conditions they encounter
by adopting flexible invasive strategies
(Wolf and Friedl, 2011). In ‘‘mesenchymal
motility,’’ invasion is achieved by coupling
polarized actin-based protrusions with
spatially restricted pericellular proteolytic
activity in bothmigrating cells and reactive
stromal cells (Wolf and Friedl, 2011). In
‘‘amoeboid motility,’’ by contrast, cancer
cells use actomyosin-based mechanical
forces to displace matrix fibrils while
adopting a rounded cell shape. Whereas
mesenchymal motility depends on RAC1,
amoeboid migration involves RHOA
(Sanz-Moreno et al., 2011). Thus, a tight
interplay between these GTPases dictatesindividual tumor cells’ invasion strategy.
Furthermore, these cells must constantly
deform and plastically adapt their nuclei
to squeeze throughnarrowgapsof intersti-
tial tissues (Wolf and Friedl, 2011). In this
issue of Developmental Cell, Navarro-Le´r-
ida et al. (2015) show that nucleocyto-
plasmic shuttling of RAC1 impacts both
cell shape—by regulating the balance of
cytoplasmic RAC1/RHOA activities—and
nuclear plasticity and deformability, thus
contributing to the regulation of cell
invasion.
Numerous guanine nucleotide ex-
change factors (GEFs) and GTPase acti-
vating proteins (GAPs), combined with a
variety of downstream effectors, enable
RAC1 to produce a diverse array of
signaling outputs (Bosco et al., 2009).
However, the differential regulation of
signaling by RAC1 in different contexts re-
mains poorly understood. Furthermore,
increasing evidence suggests that sub-
cellular compartmentalization plays a ma-
jor role in regulating the signaling output
of RAC1. In addition to the cytosol and
plasma membrane, RAC1 also localizes
to endosomes (Palamidessi et al., 2008)
and the nucleus (Kraynov et al., 2000).
RAC1 activation on early endosomes
and subsequent recycling of RAC1 tothe plasma membrane ensure polarized
signaling, leading to localized actin-based
migratory protrusions (Palamidessi et al.,
2008) and spatial restriction of RAC1
motogenic signals, which promotes me-
senchymal motility. In the nucleus, accu-
mulation of RAC1 has been linked to regu-
lation of RAC1 proteosomal degradation
(Lanning et al., 2004). Additionally, cell-
cycle-dependent accumulation of nuclear
RAC1 promotes mitotic progression (Mi-
chaelson et al., 2008). These findings sug-
gest that nucleocytoplasmic shuttling is
important for the spatial control of specific
RAC1 functions.
An elegant study by the Del Pozo group
now examines the processes that con-
tribute to, and are impacted by, RAC1 nu-
cleocytoplasmic shuttling (Navarro-Le´r-
ida et al., 2015). The authors, through a
proteomic approach, initially identified
nucleophosmin (nucleolar phosphopro-
tein B23) as a nuclear binding partner of
RAC1. B23 is a multifunctional phospho-
protein involved in ribosome biogenesis.
It shuttles between the nucleus and the
cytoplasm, interacting with a variety of
proteins and acting as a bona fide chap-
erone (Colombo et al., 2011). Indeed, the
authors show that RAC1 utilizes B23 for
nucleocytoplasmic shuttling and that the, February 9, 2015 ª2015 Elsevier Inc. 261
Figure 1. RAC1 Shuttling and Cell Invasion
Nucleocytoplasmic shuttling of RAC1 controls the organization of the nuclear membrane and the amount of RAC1 available outside the nucleus, leading to actin-
dependent changes of nuclear and cell shape linked to invasiveness. In cells, a fraction of RAC1 shuttles in and out of the nucleus. Whereas RAC1 nuclear entry is
mediated by canonical nuclear import signaling (not shown), RAC1 exit is promoted by its association with nucleophosmin (nucleolar phosphoprotein B23), a multi-
functional phosphoprotein that shuttles between the nucleus and the cytoplasm, acting as a chaperone. Nucleocytoplasmic shuttling buffers the amounts and
activity of cytoplasmic RAC1; it further controls the balance between cytosolic RAC1 and RHOA activity and signaling. Accumulation of RAC1 in the nucleus, which
is detected in aggressive cancer cells, leads to actin polymerization-dependent alterations in nuclear membrane organization, including aberrant distribution of
Lamin A/C, major structural proteins of the nuclear lamina, and Emerin, an integral nuclear transmembrane protein. These alterations correlate with dramatic
changes in nuclear shape and deformability. The increased cytoplasmic RHOA signaling and nuclear deformability, caused by nuclear accumulation of RAC1,
combine to enhance tumor cellmigratory plasticity, possibly promoting a switch fromamesenchymal to an amoeboidmodeofmotility, thus increasing invasiveness.
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Previewsinteraction with B23 depends on the
N-terminal 88 amino acids of RAC1.
Notably, the same region is also con-
tacted by RHOGDI, a guanine nucleotide
dissociation inhibitor that binds cyto-
plasmic RAC1, preventing its membrane
association. This latter finding suggests
that competition between RHOGDI and
B23 for RAC1 binding determines its
cytoplasmic/nucleoplasmic distribution.
In addition, the authors discovered two
nuclear export sequences (NES1-2) in
RAC1, indicating that canonical nuclear
export routes and B23 chaperone activity
cooperate to control the rate of RAC1 exit
from the nucleus.
Functionally, B23 expression pro-
moted, whereas B23 silencing impaired,262 Developmental Cell 32, February 9, 2015RAC1 nuclear export. Interestingly, B23
interacted primarily with GTP-bound
RAC1, suggesting that nuclear RAC1
might be active. The use of a FRET-
RAC1 sensor confirmed this prediction.
More strikingly, forced nuclear accumula-
tion of RAC1, by ectopic expression
either of the wild-type or of NES mutants,
dramatically deformed nuclear shape.
Under these conditions, RAC1 displayed
a nearly vesicular nuclear distribution,
with obvious accumulation in discrete
patches. These alterations were accom-
panied by the aberrant redistribution of
Lamin A/C, major structural proteins of
the nuclear lamina, and Emerin, an inte-
gral nuclear transmembrane protein. Acti-
vated nuclear RAC1 also partitioned intoª2015 Elsevier Inc.nuclear membrane microdomains, similar
to liquid-ordered regions of the plasma
membrane. This suggested that RAC1
might act as a nuclear membrane
organizer for the assembly of signaling
platforms. These platforms contain fila-
mentous actin and the ARP2/3 complex.
Additionally, both nuclear deformation
and altered nuclear shape depended
on RAC1-driven ARP2/3 activation and
actin polymerization. Thus, the first
functional consequence of accumulated
nuclear RAC1 is to promote nuclear
envelope-localized actin dynamics that
drive nuclear deformation and plasticity
(Figure 1).
RAC1 nuclear accumulation was
mirrored by a decrease in active,
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Previewscytoplasmic RAC1, with a concomitant
elevation of RHOA-GTP. This shift in the
cytoplasmic ratio of RAC1 to RHOA activ-
ity led to RHOA-dependent activation of
ROCK and increased actomyosin con-
tractility, mimicking biochemical changes
known to promote a switch from amesen-
chymal to an amoeboid mode of migra-
tion. Additionally, pericellular proteolytic
activity increased in cells depleted for
B23 and depended on RHOA-ROCK ac-
tivity. Functionally, accumulation of nu-
clear RAC1 enabled cells to invade a 3D
matrix and to migrate through transwell
filters of limited pore size, where nuclear
deformability becomes a critical factor.
Thus, nuclear sequestration of RAC1 re-
sults in elevated RHOA signaling, actomy-
osin contractility, and increased nuclear
plasticity that combine to promote tumor
cell invasiveness (Figure 1). Not surpris-
ingly, the authors found nuclear accu-
mulation of RAC1 in aggressive lung and
prostate carcinoma and in an acute
myeloid leukemia caused by B23 muta-tions that result in inappropriate cyto-
plasmic relocalization of the protein.
Outstanding questions remain. For
example, how is nuclear RAC1 activated?
What are the key RAC1 effectors pro-
moting ARP2/3-dependent nuclear actin
polymerization? Is nuclear accumula-
tion of RAC1 sufficient to promote amoe-
boid motility in 3D? What causes the
accumulation of RAC1 in the nucleus of
aggressive tumors? Although future
studies will be required to address these
issues, the study from Navarro-Le´rida
et al. provides insight into how nucleocy-
toplasmic shuttling of RAC1 controls nu-
clear and cellular plasticity in tumors by
spatially restricting RAC1 activity.REFERENCES
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